0.38
Curis Inc Aktie (CRIS) Neueste Nachrichten
CRIS Q1 2026 Earnings: Deep EPS Miss Highlights Pre-Revenue Challenges Amid Strategic PivotQuarterly Earnings - newsline.com
Curis stock (US2312691006): Cancer biotech faces Nasdaq compliance deadline after reverse stock spli - AD HOC NEWS
Q1 2026 Curis Inc Earnings Call Transcript - GuruFocus
Curis (NASDAQ: CRIS) plans reverse stock split to address Nasdaq bid price - Stock Titan
CRIS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Curis Inc. (CRIS) Surges 8.33%: Momentum Builds Above Key SupportVolatility Stop - newsline.com
CRIS News | CURIS INC (NASDAQ:CRIS) - ChartMill
CRIS Q1 2026 Earnings: Significant EPS Miss Highlights Ongoing Pre-Revenue ChallengesEarnings Deceleration Risk - The Legal Advocate
CRIS Q1 2026 Earnings: Significant EPS Miss as Biotech Advances Pipeline Without RevenueRevenue Per Share - The Legal Advocate
Curis Inc. Q1 2026 Earnings: Deep EPS Miss as Pre-Revenue Biotech Continues DevelopmentShare Dilution Risk - Newser
CRIS Q1 2026 Earnings: Significant EPS Miss Amidst Operational UpdatesEPS Growth Rate - The Legal Advocate
Curis Shareholders Approve Expanded Capital Structure and Governance - TipRanks
Curis (NASDAQ: CRIS) wins shareholder approval to double authorized common stock - Stock Titan
Curis stock (US2312691006): Phase 1 data update lifts attention - AD HOC NEWS
Curis Inc Annual Shareholders Meeting Transcript - GuruFocus
CRIS: All five shareholder proposals, including director elections and share increase, were approved - TradingView
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Da - GuruFocus
Curis Faces Nasdaq Delisting Determination, Plans Appeal Hearing - TipRanks
Why Curis (CRIS) Just Dropped -2.08% — What to Watch 2026-05-18Risk Reversal - The Legal Advocate
Curis stock (US2312691006): cancer pipeline update keeps investors cautious - AD HOC NEWS
Armistice Capital (NASDAQ: CRIS) reports 4.99% ownership of Curis - Stock Titan
JonesTrading Maintains Curis(CRIS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Thomas Satterfield holds 3.96M shares as Curis (CRIS) ownership amended - Stock Titan
Curis, Inc. (NASDAQ:CRIS) Q1 2026 Earnings Call Transcript - Insider Monkey
Curis Q1 2026 earnings preview - MSN
Curis Inc. Earnings Call Highlights Clinical Momentum - TipRanks
Curis Q1 2026 Deep Dive: EPS Misses by 331.0%, Revenue Down 100% - AlphaStreet
Curis, Inc. (CRIS) Reports Q1 2026 Loss and Updates on Clinical Trials - GuruFocus
CURIS INC 1Q 2026: Revenue $0 Net income ($24.2M), EPS ($1.25) — 10-Q Summary - TradingView
Curis (NASDAQ: CRIS) posts larger Q1 2026 loss and warns on going concern - Stock Titan
Curis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Curis anticipates TakeAim CLL initial 5-patient dosing by mid-2026 while projecting cash runway into second half of '27 - MSN
Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in L - GuruFocus
Curis (CRIS) Expects Sufficient Funding to Support Operations Un - GuruFocus
Earnings call transcript: Curis Q1 2026 reveals widened net loss - Investing.com UK
Curis (CRIS) Reports Q1 Revenue Below Expectations - GuruFocus
Curis Q1 2026 Earnings Call Transcript - MarketBeat
Curis (CRIS) Q1 Miss: EPS -$1.25 vs -$0.40 est, Revenue $0 vs $1 - GuruFocus
Curis Provides First Quarter 2026 Business Update - GuruFocus
Curis Sees Cash Runway Into the 2H of 2027 >CRIS - Moomoo
Earnings call transcript: Curis Q1 2026 reveals widened net loss By Investing.com - Investing.com Nigeria
Curis Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Curis Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Curis reports Q1 loss, expects CLL trial milestone by mid-2026 - Investing.com South Africa
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):